Live Breaking News & Updates on Nasdaq Atra

Stay updated with breaking news from Nasdaq atra. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of "Hold" from Analysts

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) has earned a consensus recommendation of “Hold” from the three research firms that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation. The average 12-month price objective among brokerages that have updated their coverage on the stock in […] ....

United States , Atara Biotherapeutics Inc , Sg Americas Securities , Redmile Group , Advisor Group , Vontobel Holding Ltd , Josh Arnold Investment Consultant , Get Free Report , Marketbeat Ratings , Arnold Investment Consultant , Get Free , Atara Biotherapeutics , Nasdaq Atra ,

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Short Interest Update

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 11,030,000 shares, a growth of 8.8% from the February 29th total of 10,140,000 shares. Based on an average daily volume of 3,500,000 shares, […] ....

United States , Renaissance Technologies , Atara Biotherapeutics Inc , Goldman Sachs Group Inc , Atara Biotherapeutics Company Profile , Wasatch Advisors Inc , Get Free Report , Street Corp , Goldman Sachs Group , Sachs Group , Atara Biotherapeutics , Nasdaq Atra ,

Brokerages Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Price Target at $28.00

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) have been given an average recommendation of “Hold” by the three research firms that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation. The average twelve-month target price among brokers that have issued ratings on the […] ....

Hong Kong , United States , Tower Research Capital , Envestnet Asset Management Inc , Hong Kong Ltd , Atara Biotherapeutics Company Profile , Atara Biotherapeutics Inc , Get Free Report , Marketbeat Ratings , Kong Ltd , Research Capital , Sigma Investments , Asset Management , Quantbot Technologies , Get Free , Atara Biotherapeutics , Nasdaq Atra ,

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of "Hold" by Analysts

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) has received an average recommendation of “Hold” from the four research firms that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year target price […] ....

United States , Hong Kong , Carol Giltner Gallagher , Tower Research Capital , Hong Kong Ltd , Atara Biotherapeutics Inc , Envestnet Asset Management Inc , Get Free Report , Director Carol Giltner Gallagher , Kong Ltd , Research Capital , Sigma Investments , Asset Management , Quantbot Technologies , Get Free , Atara Biotherapeutics , Nasdaq Atra ,

Brokerages Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Target Price at $28.00

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) have earned a consensus rating of “Hold” from the four ratings firms that are currently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month […] ....

United States , Carol Giltner Gallagher , Baupost Group , Atara Biotherapeutics Inc , Atara Biotherapeutics Company Profile , Blackrock Inc , Redmile Group , Jpmorgan Chase Co , Get Free Report , Marketbeat Ratings , Director Carol Giltner Gallagher , Street Corp , Get Free , Atara Biotherapeutics , Nasdaq Atra ,